Here are the DEF 14A proxy statements from Calidi Biotherapeutics, Inc. (CLDI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CLDI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLDI filings page.
Calidi Biotherapeutics, Inc. is asking stockholders to vote at a virtual annual meeting on June 12, 2026, with a record date of April 17, 2026. Proposals include electing one Class III director, ratifying CBIZ CPAs P.C. as auditor, and authorizing a reverse stock split between 1-for-2 and 1-for-16 at the board’s discretion.
Stockholders will also consider increasing the 2023 Equity Incentive Plan share authorization from 282,815 to 1,950,000 shares and an adjournment proposal to allow extra time to gather votes if needed. There were 15,228,625 shares of voting common stock outstanding as of the record date.